Home > Insider Trading > Filing (0001656472-21-000029)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1656472	Cronos Group Inc.	CRON	Medicinal Chemicals & Botanical Products (2833)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1797199	Ryan Michael Gorenstein	111 Peter Street, Suite 300 Toronto A6 M5V 2H1	Executive Chairman	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2021-03-08	1,200,000	$0.97	9,632,536	No	4	M	Direct
Common Shares	Disposition	2021-03-08	410,589	$9.54	9,221,947	No	4	F	Direct
Common Shares	Disposition	2021-03-09	185,000	$10.00	9,036,947	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	COMMON SHARE OPTION (right to buy)	Disposition	2021-03-08	1,200,000	$0.00	1,200,000	$0.97

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2021-10-06	No	4	M	Direct

Footnotes

The price reported was converted from the Canadian exercise price of C$1.23 to U.S. dollars using an exchange rate of C$1.00 to US$0.7887 as reported by Bloomberg as of March 5, 2021.
Cronos Group Inc. (the "Company") withheld 410,589 common shares underlying the options for payment of the exercise price and to cover applicable withholding taxes, using the closing price of the Company's common shares on March 5, 2021 of C$12.09 as reported on the Toronto Stock Exchange.
The price reported is in U.S. dollars based on the exchange rate of C$1.00 to US$0.7887 as reported by Bloomberg as of March 5, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $10.07, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
The options were granted October 6, 2016 and vest in monthly installments over a four-year period.